이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Mirogabalin vs. Melatonin for Pain and Anxiety After Total Knee Arthroplasty Under Spinal Anesthesia

2026년 11월 18일 업데이트: Kerollos Moneer Neseem Mikhael, Beni-Suef University

Mirogabalin Versus Melatonin for Perioperative Anxiolysis and Opioid-Sparing Analgesia After Total Knee Arthroplasty Under Spinal Anesthesia: A Double-Blind, Randomized, Placebo-Controlled Trial

Total knee arthroplasty (TKA) is frequently associated with moderate-to-severe postoperative pain, substantial opioid consumption, and preoperative anxiety. Although spinal anesthesia is preferred for TKA, it does not provide prolonged analgesia after the block resolves.

This prospective, randomized, double-blind, placebo-controlled trial aims to evaluate and compare the efficacy of perioperative oral mirogabalin versus melatonin versus placebo as opioid-sparing analgesic adjuncts in patients undergoing elective unilateral TKA under spinal anesthesia. The primary objective is to assess their impact on postoperative pain intensity and perioperative anxiety levels.

연구 개요

상세 설명

Preoperative anxiety affects 30% to 70% of patients undergoing total knee arthroplasty (TKA) and can exacerbate postoperative pain, increase opioid consumption, and delay recovery. Multimodal perioperative optimization within Enhanced Recovery After Surgery (ERAS) protocols is essential to address these challenges.

Mirogabalin is a novel, selective ligand of the α₂δ subunit of voltage-gated calcium channels with a long dissociation half-life, demonstrating analgesic and anxiolytic properties. Melatonin is an endogenous pineal hormone with well-characterized chronobiotic, sedative, anxiolytic, and antinociceptive actions. Despite their potential, no randomized controlled trial has directly compared mirogabalin and melatonin for perioperative optimization in TKA under spinal anesthesia.

Eligible consenting participants (aged 50-70 years, ASA I-III, scheduled for primary elective unilateral TKA under spinal anesthesia) will be randomized (1:1:1) to one of three parallel groups:

  1. Mirogabalin Group: Oral mirogabalin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, 10:00 PM on surgery day, and at 10:00 AM and 10:00 PM on Postoperative Day 1.
  2. Melatonin Group: Oral melatonin administered at 10:00 PM the night before surgery, 1 hour before spinal anesthesia, and 10:00 PM on surgery day; matching placebo at 10:00 AM on Postoperative Day 1, followed by melatonin at 10:00 PM on Postoperative Day 1.
  3. Placebo Group: Matching placebo administered at identical time points.

All patients will receive standardized intraoperative spinal anesthesia (hyperbaric bupivacaine + fentanyl) and standardized background multimodal analgesia (paracetamol, ketorolac, and intraoperative dexamethasone).

Outcomes assessed up to 48 hours postoperatively include Numeric Rating Scale (NRS) pain scores, Amsterdam Preoperative Anxiety and Information Scale (APAIS) scores, 24-hour and 48-hour cumulative opioid (nalbuphine) consumption, time to first rescue analgesia, sedation level (MOOA/S), sleep quality (SQS), time to first mobilization, hemodynamic stability, and adverse events.

연구 유형

중재적

등록 (추정된)

78

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Banī Suwayf, 이집트
        • Beni-Suef University Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

50년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 50 to 70 years.
  • American Society of Anesthesiologists (ASA) physical status I, II, or III.
  • Scheduled for elective primary unilateral total knee arthroplasty (TKA) under spinal anesthesia.
  • Body Mass Index (BMI) between 18.5 and 35 kg/m².
  • Able to understand and complete study questionnaires (APAIS, NRS) in the local language.
  • Provision of signed written informed consent.

Exclusion Criteria:

  • Contraindication to spinal anesthesia (e.g., coagulopathy, local puncture site infection, severe spinal deformity, or patient refusal).
  • Known hypersensitivity or allergy to mirogabalin, melatonin, gabapentinoids, or study medication excipients.
  • Pre-existing chronic pain syndrome requiring long-term opioid, gabapentinoid, or melatonin therapy.
  • Severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m²) or end-stage renal disease.
  • Severe hepatic impairment (Child-Pugh class C).
  • Psychiatric illness impairing comprehension or cooperation (e.g., dementia, active psychosis) or current treatment with anxiolytics, antipsychotics, or antidepressants.
  • Current pregnancy or breastfeeding.
  • Revision arthroplasty, bilateral TKA procedures, or intraoperative conversion to general anesthesia.
  • Known sleep disorder under active pharmacological treatment, or current shift-work disorder.
  • Participation in another interventional drug trial within 30 days prior to enrollment.
  • Inability to complete visual/numeric pain and anxiety scales due to visual, cognitive, or language barriers.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group G (Mirogabalin)

Patients receive oral mirogabalin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on the first postoperative day (Postoperative Day 1). All participants receive standardized spinal anesthesia (hyperbaric bupivacaine 0.5% + fentanyl 25 mcg) and multimodal background analgesia (paracetamol 1 g IV q6h, ketorolac 30 mg IV q12h, and intraoperative dexamethasone 8 mg IV).

Oral mirogabalin 10 mg tablet administered per protocol schedule (5 total doses perioperatively).

활성 비교기: Group M (Melatonin)

Patients receive oral melatonin 10 mg at 10:00 PM on the night before surgery, 1 hour before planned spinal anesthesia, and 10:00 PM on the day of surgery. On Postoperative Day 1, patients receive a matching placebo tablet at 10:00 AM (to preserve blinding), followed by melatonin 10 mg at 10:00 PM. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.

Oral melatonin 10 mg tablet administered per protocol schedule (4 active doses + 1 placebo dose at 10:00 AM POD 1).

위약 비교기: Group P (Placebo)

Patients receive matching oral placebo tablets administered at corresponding time points: 10:00 PM the night before surgery, 1 hour before planned spinal anesthesia, 10:00 PM on the day of surgery, and at 10:00 AM and 10:00 PM on Postoperative Day 1. All participants receive standardized spinal anesthesia and identical background multimodal analgesia.

Matching inert oral placebo tablet administered to Group P (5 total doses) and Group M (1 dose at 10:00 AM POD 1).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Postoperative Pain Intensity Scores
기간: Assessed at 2, 12, 24, and 48 hours postoperatively.

Assessed using the Numeric Rating Scale (NRS), where scores range from 0 to 10 (0 = "no pain", 10 = "worst possible pain"). Lower scores represent a more favorable clinical outcome (less pain intensity), whereas higher scores represent an unfavorable outcome.

Assessed at 2, 12, 24, and 48 hours postoperatively.
Perioperative Anxiety Scores
기간: Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.

Assessed using the anxiety subscale of the Amsterdam Preoperative Anxiety and Information Scale (APAIS). The anxiety subscale consists of 4 items rated on a 5-point Likert scale (1 = not at all, 5 = extremely), with total anxiety scores ranging from 4 to 20. Lower scores represent a more favorable clinical outcome (lower anxiety), whereas higher scores represent an unfavorable outcome.

Preoperatively (holding area, 60-120 minutes before spinal anesthesia), and postoperatively at 2 and 12 hours.

2차 결과 측정

결과 측정
측정값 설명
기간
Total Cumulative Postoperative Opioid Consumption
기간: First 24 and 48 hours postoperatively.

Total intravenous nalbuphine consumption measured in milligrams (mg) administered as rescue analgesia during the first 24 and 48 postoperative hours. Lower cumulative dose values represent a more favorable outcome (greater opioid-sparing effect).

First 24 and 48 hours postoperatively.
Time to First Request for Rescue Analgesia
기간: Up to 48 hours postoperatively.

Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU, time zero) to the first administration of rescue IV nalbuphine for NRS pain score >= 4. Longer duration (higher values in minutes) represents a more favorable outcome (prolonged postoperative analgesia).

Up to 48 hours postoperatively.
Postoperative Sedation Scores
기간: Assessed at 2, 12, 24, and 48 hours postoperatively.

Evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOOA/S) scale, ranging from 0 (does not respond to deep algic stimulus) to 5 (responds readily to name spoken in normal tone). A score of 5 represents alertness (favorable recovery state), whereas lower scores indicate deeper sedation (unfavorable/excessive drug-induced sedation).

Assessed at 2, 12, 24, and 48 hours postoperatively.
Incidence of Postoperative Nausea and Vomiting and Requirement for Rescue Antiemetics
기간: Assessed at 2, 12, 24, and 48 hours postoperatively.

Number of participants experiencing nausea or vomiting and requiring rescue antiemetic therapy. A lower incidence (fewer participants affected) represents a favorable outcome.

Assessed at 2, 12, 24, and 48 hours postoperatively.
Postoperative Sleep Quality Score
기간: Assessed at 48 hours postoperatively.

Assessed using the Single-Item Sleep Quality Scale (SQS), where overall sleep quality over the 48-hour postoperative period is rated on a 0 to 10 scale (0 = terrible, 10 = excellent). Higher scores represent a more favorable outcome (better sleep quality).

Assessed at 48 hours postoperatively.
Time to First Postoperative Mobilization
기간: Up to 48 hours postoperatively.

Time elapsed (in hours) from arrival in the PACU to first achieving bedside sitting and subsequent assisted ambulation. Shorter duration (lower values in hours) represents a more favorable recovery outcome.

Up to 48 hours postoperatively.
Incidence of Treatment-Emergent Adverse Events
기간: Up to 48 hours postoperatively.

Number of participants experiencing adverse drug events, including dizziness, excessive somnolence, headache, pruritus, constipation, and urinary retention. A lower incidence represents a more favorable safety profile.

Up to 48 hours postoperatively.
Incidence of Intraoperative Hypotension and Bradycardia
기간: Intraoperatively (from spinal injection to completion of surgery).

Number of participants experiencing spinal-anesthesia-related hypotension (mean arterial pressure drop > 20% from baseline requiring IV fluids/ephedrine) or bradycardia (heart rate < 50 bpm requiring IV atropine). A lower incidence represents a more favorable hemodynamic stability profile.

Intraoperatively (from spinal injection to completion of surgery).
Patient Satisfaction With Perioperative Analgesia
기간: Assessed at 24 hours postoperatively.

Evaluated on a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied). Higher scores represent a more favorable outcome.

Assessed at 24 hours postoperatively.
Length of Postoperative Hospital Stay
기간: From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.

Duration of hospital stay measured in hours from completion of surgery until meeting formal discharge criteria. Shorter stay duration (lower values) represents a more favorable outcome.

From completion of surgery (arrival in the PACU) until the date and time of meeting formal hospital discharge criteria, assessed up to 7 days postoperatively.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2027년 5월 1일

연구 완료 (추정된)

2027년 6월 1일

연구 등록 날짜

최초 제출

2026년 11월 15일

QC 기준을 충족하는 최초 제출

2026년 11월 18일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 18일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data (IPD) underlying the published results (including baseline demographics, intervention group allocation, pain scores, anxiety scores, cumulative opioid consumption, and adverse event data) will be made available to qualified researchers upon reasonable request to the

IPD 공유 기간

Beginning 6 months and ending 3 years following article publication

IPD 공유 액세스 기준

Available to academic researchers who provide a methodologically sound proposal approved by the Beni-Suef University Research Ethics Committee

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다